AMPLITUDE-O

Definition

The cardiovascular outcomes trial of efpeglenatide (a long-acting GLP-1 receptor agonist) in adults with type 2 diabetes at high cardiovascular risk. Gerstein and colleagues (NEJM 2021) reported a 27% relative reduction in three-point MACE — efpeglenatide was not subsequently marketed in the US.

AMPLITUDE-O trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Looking for more depth?

• AMPLITUDE-O trial deep-dive
• Browse the full GLP-1 glossary (124 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers